Filed (PHiled). Greater than 1-2 years since publication

Metabolic reprogramming, oxidative stress, and pulmonary hypertension

Marissa D. Pokharel, David P. Marciano, Panfeng Fu, Maria Clara Franco, Hoshang Unwalla, Kim Tieu, Jeffrey R. Fineman, Ting Wang, Stephen M. BlackFlorida International University.  University of California San Francisco. United States Redox BiologyRedox Biol 2023; DOI: 10.1016/j.redox.2023.102797 AbstractMitochondria are highly dynamic organelles essential for cell metabolism, growth, and function. It is becoming increasingly clear that […]

Metabolic reprogramming, oxidative stress, and pulmonary hypertension Read More »

PIF1 Promotes Autophagy to Inhibit Chronic Hypoxia Induced Apoptosis of Pulmonary Artery Endothelial Cells

Yujing Zhao, Juan Wu, Shuai Guan, Ting Xue, Xiaolei Wei, Dawei Cao, Pengzhou Kong, Xinri ZhangThe First Hospital of Shanxi Medical University. The First People’s Hospital of Datong.China International Journal of Chronic Obstructive Pulmonary DiseaseInt J Chron Obstruct Pulmon Dis 2023; 18: 1319-1332DOI: 10.2147/COPD.S406453 AbstractPurpose: Pulmonary artery hypertension (PAH) is a common complication of chronic obstructive pulmonary

PIF1 Promotes Autophagy to Inhibit Chronic Hypoxia Induced Apoptosis of Pulmonary Artery Endothelial Cells Read More »

The cascade screening in heritable forms of pulmonary arterial hypertension

Nidhy P. Varghese, Akhilesh A. Padhye, Pilar L. Magoulas, George B. Mallory, Fadel E. Ruiz, Sandeep SahayBaylor College of Medicine Texas Children’s Hospital Houston. Houston Methodist Hospital. Weill Cornell Medical College.United States Pulmonary CirculationPulm Circ 2023;DOI: 10.1002/pul2.12259 AbstractHeritable pulmonary artery hypertension (HPAH) is an increasingly recognized type of pulmonary arterial hypertension, in both pediatric and adult

The cascade screening in heritable forms of pulmonary arterial hypertension Read More »

Advances in epigenetic modifications of autophagic process in pulmonary hypertension

Min Mao, Shasha Song, Xin Li, Jiayao Lu, Jie Li, Weifang Zhao, Hanmin Liu, Jingxin Liu, Bin ZengWest China Second University Hospital and Sichuan University. School of Life Sciences of Fudan University. Shenzhen Technology University. Shenzhen Reyson Biotechnology Company. North China Pharmaceutical Company. Hebei Huamin Pharmaceutical Company.China Frontiers in ImmunologyFront Immunol 2023; 14:DOI: 10.3389/fimmu.2023.1206406 AbstractPulmonary hypertension

Advances in epigenetic modifications of autophagic process in pulmonary hypertension Read More »

Neurodevelopmental Outcomes of Preterm Infants Born <29 Weeks with Bronchopulmonary Dysplasia-Associated Pulmonary Hypertension: A Multicenter Study

Soumya R. Thomas, Sunil K. Jain, Prashanth Murthy, Chacko J. Joseph, Amuchou Soraisham, Selphee Tang, Aliyah Dosani, Abhay LodhaUniversity of Calgary and Alberta Children’s Hospital. University of Texas Medical Branch. Mount Royal University.Canada and United States American Journal of PerinatologyAm J Perinatol 2023; DOI: 10.1055/a-2121-8878 AbstractObjective: This study aimed to determine neurodevelopmental outcomes of preterm infants born

Neurodevelopmental Outcomes of Preterm Infants Born <29 Weeks with Bronchopulmonary Dysplasia-Associated Pulmonary Hypertension: A Multicenter Study Read More »

Vein of Galen aneurysmal malformation in newborns: a retrospective study to describe a paradigm of treatment and identify risk factors of adverse outcome in a referral center

Silvia Buratti, Marisa Mallamaci, Giulia Tuo, Mariasavina Severino, Domenico Tortora, Costanza Parodi, Andrea Rossi, Francesco Pasetti, Lucio Castellan, Valeria Capra, Ferruccio Romano, Patrizia De Marco, Marco Pavanello, Gianluca Piatelli, Dario Paladini, Maria Grazia Calevo, Andrea Moscatelli, on behalf of the IGG VGAM TeamIRCCS Istituto Giannina Gaslini and University of Genoa. San Martino Polyclinic Hospital. Italy

Vein of Galen aneurysmal malformation in newborns: a retrospective study to describe a paradigm of treatment and identify risk factors of adverse outcome in a referral center Read More »

Ventricular global function index is associated with clinical outcomes in pediatric pulmonary hypertension

Hieu T. Ta, Paul J. Critser, Michal Schäfer, Nicholas J. Ollberding, Michael D. Taylor, Michael V. Di Maria, Russel Hirsch, D. Dunbar Ivy, Benjamin S. FrankCincinnati Children’s Hospital Medical Center and University of Cincinnati. University of Colorado. United States Journal of Cardiovascular Magnetic ResonanceJ Cardiovasc Magnet Reson 2023; 25DOI: 10.1186/s12968-023-00947-8 AbstractBackground: Multiple right ventricular (RV) metrics have

Ventricular global function index is associated with clinical outcomes in pediatric pulmonary hypertension Read More »

Histologic features and decreased lung FOXF1 gene expression in severe bronchopulmonary dysplasia without a genetic diagnosis of alveolar capillary dysplasia

Csaba Galambos, J. Wells Logan, Pawel Stankiewicz, Przemyslaw Szafranski, Carol Zalles, Jose Gonzales, Sfurti Nath, Shalinkumar Patel, Steven H. AbmanUniversity of Colorado Anschutz School of Medicine. Wolfson Children’s Hospital and the University of Florida College of Medicine. Baylor College of Medicine.United States Pediatric PulmonologyPediatr Pulmonol 2023; DOI: 10.1002/ppul.26571 AbstractWe report the case of a preterm infant

Histologic features and decreased lung FOXF1 gene expression in severe bronchopulmonary dysplasia without a genetic diagnosis of alveolar capillary dysplasia Read More »

Reverse Potts for the Treatment of Severe Idiopathic Pulmonary Hypertension in Children

Marcelo Frederigue de Castro, Edmundo Clarindo Oliveira, Maria Carmo Pereira Nunes, Carla de Oliveira, Maria Gabriela Costa de Almeida, Jose Augusto Almeida BarbosaHospital Vila da Serra. Universidade Federal de Minas Gerais. Hospital Felicio Rocho.Brazil Brazilian Journal of Cardiovascular SurgeryBraz J Cardiovasc Surg 2023; DOI: 10.21470/1678-9741-2022-0320 AbstractIdiopathic pulmonary arterial hypertension is a rare and progressive disease with

Reverse Potts for the Treatment of Severe Idiopathic Pulmonary Hypertension in Children Read More »

Cost-utility of ambrisentan and bosentan for pediatric pulmonary arterial hypertension

Jefferson Antonio Buendia, Diana Guerrero Patino, Erika Fernanda LindarteUniversity of Antioquia. University of Oxford. Columbia and United Kingdom Expert Review of Pharmacoeconomic and Outcomes ResearchExpert Rev Pharmacoecon Outcomes Res 2023; DOI: 10.1080/14737167.2023.2233698 AbstractIntroduction: Despite the increasing evidence supporting the efficacy of ambrisentan and bosentan in improving functional classes among pediatric patients with pulmonary arterial hypertension (PAH), there

Cost-utility of ambrisentan and bosentan for pediatric pulmonary arterial hypertension Read More »

Scroll to Top